Use of methyl salicylate as a simulant to predict the percutaneous absorption of sulfur mustard. 2001

J E Riviere, and C E Smith, and K Budsaba, and J D Brooks, and E J Olajos, and H Salem, and N A Monteiro-Riviere
Center for Cutaneous Toxicology and Residue Pharmacology, College of Veterinary Medicine, North Carolina State University, Raleigh, NC 27606, USA. Jim_Riviere@NCSU.EDU

Exposure to chemical vesicants such as sulfur mustard (HD) continues to be a threat to military forces requiring protectant strategies to exposure to be evaluated. Methyl salicylate (MS) has historically been the simulant of choice to assess HD exposure. The purpose of this study was to compare the percutaneous absorption and skin deposition of MS to HD in the isolated perfused porcine skin flap (IPPSF). The HD data were obtained from a previously published study in this model wherein 400 microg cm(-2) of ](14)C[-MS or ](14)C[-HD in ethanol were topically applied to 16 IPPSFs and experiments were terminated at 2, 4 or 8 h. Perfusate was collected at increasing time intervals throughout perfusion. Radioactivity was determined in perfusate and skin samples. Perfusate flux profiles were fitted to a bi-exponential model Y(t) = A(e(-bt) - e(-dt)) and the area under the curve (AUC), peak flux and time to peak flux were determined. Sulfur mustard had more pronounced and rapid initial flux parameters (P < 0.05). The AUCs determined from observed and model-predicted parameters were not statistically different, although the mean HD AUC was 40--50% greater than MS. The HD skin and fat levels were up to twice those seen with MS, but had lower stratum corneum and residual skin surface concentrations (P < 0.05). Compared with other chemicals studied in this model, HD and MS cutaneous disposition were very similar, supporting the use of MS as a dermal simulant for HD exposure.

UI MeSH Term Description Entries
D008954 Models, Biological Theoretical representations that simulate the behavior or activity of biological processes or diseases. For disease models in living animals, DISEASE MODELS, ANIMAL is available. Biological models include the use of mathematical equations, computers, and other electronic equipment. Biological Model,Biological Models,Model, Biological,Models, Biologic,Biologic Model,Biologic Models,Model, Biologic
D009151 Mustard Gas Severe irritant and vesicant of skin, eyes, and lungs. It may cause blindness and lethal lung edema and was formerly used as a war gas. The substance has been proposed as a cytostatic and for treatment of psoriasis. It has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP-85-002, 1985) (Merck, 11th ed). Dichlorodiethyl Sulfide,Sulfur Mustard,Bis(beta-chloroethyl) Sulfide,Di-2-chloroethyl Sulfide,Mustardgas,Psoriazin,Yellow Cross Liquid,Yperite,Di 2 chloroethyl Sulfide,Gas, Mustard,Mustard, Sulfur,Sulfide, Di-2-chloroethyl,Sulfide, Dichlorodiethyl
D002250 Carbon Radioisotopes Unstable isotopes of carbon that decay or disintegrate emitting radiation. C atoms with atomic weights 10, 11, and 14-16 are radioactive carbon isotopes. Radioisotopes, Carbon
D003879 Dermatologic Agents Drugs used to treat or prevent skin disorders or for the routine care of skin. Agent, Dermatologic,Agent, Dermatological,Agents, Dermatologic,Dermatologic Agent,Dermatological Agents,Agents, Dermatological,Dermatological Agent
D005404 Fixatives Agents employed in the preparation of histologic or pathologic specimens for the purpose of maintaining the existing form and structure of all of the constituent elements. Great numbers of different agents are used; some are also decalcifying and hardening agents. They must quickly kill and coagulate living tissue. Fixative,Pickling Agents,Agents, Pickling
D000279 Administration, Cutaneous The application of suitable drug dosage forms to the skin for either local or systemic effects. Cutaneous Drug Administration,Dermal Drug Administration,Drug Administration, Dermal,Percutaneous Administration,Skin Drug Administration,Transcutaneous Administration,Transdermal Administration,Administration, Dermal,Administration, Transcutaneous,Administration, Transdermal,Cutaneous Administration,Cutaneous Administration, Drug,Dermal Administration,Drug Administration, Cutaneous,Skin Administration, Drug,Administration, Cutaneous Drug,Administration, Dermal Drug,Administration, Percutaneous,Administrations, Cutaneous,Administrations, Cutaneous Drug,Administrations, Dermal,Administrations, Dermal Drug,Administrations, Percutaneous,Administrations, Transcutaneous,Administrations, Transdermal,Cutaneous Administrations,Cutaneous Administrations, Drug,Cutaneous Drug Administrations,Dermal Administrations,Dermal Drug Administrations,Drug Administrations, Cutaneous,Drug Administrations, Dermal,Drug Skin Administrations,Percutaneous Administrations,Skin Administrations, Drug,Skin Drug Administrations,Transcutaneous Administrations,Transdermal Administrations
D000327 Adsorption The adhesion of gases, liquids, or dissolved solids onto a surface. It includes adsorptive phenomena of bacteria and viruses onto surfaces as well. ABSORPTION into the substance may follow but not necessarily. Adsorptions
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D012459 Salicylates The salts or esters of salicylic acids, or salicylate esters of an organic acid. Some of these have analgesic, antipyretic, and anti-inflammatory activities by inhibiting prostaglandin synthesis. Salicylate,Salicylic Acids,Acids, Salicylic
D012867 Skin The outer covering of the body that protects it from the environment. It is composed of the DERMIS and the EPIDERMIS.

Related Publications

J E Riviere, and C E Smith, and K Budsaba, and J D Brooks, and E J Olajos, and H Salem, and N A Monteiro-Riviere
November 2018, Talanta,
J E Riviere, and C E Smith, and K Budsaba, and J D Brooks, and E J Olajos, and H Salem, and N A Monteiro-Riviere
September 2022, Nano letters,
J E Riviere, and C E Smith, and K Budsaba, and J D Brooks, and E J Olajos, and H Salem, and N A Monteiro-Riviere
May 1978, Fukuoka igaku zasshi = Hukuoka acta medica,
J E Riviere, and C E Smith, and K Budsaba, and J D Brooks, and E J Olajos, and H Salem, and N A Monteiro-Riviere
August 2020, Advanced materials (Deerfield Beach, Fla.),
J E Riviere, and C E Smith, and K Budsaba, and J D Brooks, and E J Olajos, and H Salem, and N A Monteiro-Riviere
January 1986, European journal of clinical pharmacology,
J E Riviere, and C E Smith, and K Budsaba, and J D Brooks, and E J Olajos, and H Salem, and N A Monteiro-Riviere
January 2002, Journal of applied toxicology : JAT,
J E Riviere, and C E Smith, and K Budsaba, and J D Brooks, and E J Olajos, and H Salem, and N A Monteiro-Riviere
September 2016, Journal of colloid and interface science,
J E Riviere, and C E Smith, and K Budsaba, and J D Brooks, and E J Olajos, and H Salem, and N A Monteiro-Riviere
June 2021, Journal of hazardous materials,
J E Riviere, and C E Smith, and K Budsaba, and J D Brooks, and E J Olajos, and H Salem, and N A Monteiro-Riviere
July 2017, ACS applied materials & interfaces,
J E Riviere, and C E Smith, and K Budsaba, and J D Brooks, and E J Olajos, and H Salem, and N A Monteiro-Riviere
November 1995, The Journal of pharmacy and pharmacology,
Copied contents to your clipboard!